







^aThe safety follow up period is calculated to be 18 weeks post last double-blind brazikumab/brazikumab placebo dose.

Figure 1
(continuation)

V_H1 (SEQ ID NO: 1)

QVQLVESGGGVVQPGRSLRLSCAASGFTSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYADSVKGR
CDR 1 CDR 2
FTISRDNSKNTILYQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS
CDR 3

V_L1 (SEQ ID NO: 2)

QSVLTQPPSVSGAPGQRVTISCTIGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPS
CDR 1 CDR 2
GVPDFSGSKSGTSASLATGLQAEDEADYYCQSYDSSLSCGWVFGGGLRLTVL
CDR 3

Figure 2